---
title: CDMO Daily News — August 21, 2026
slug: daily-news-2026-08-21-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: August 21 CDMO daily: Piramal Pharma Increases Yapan Bio Stake to 74% for $7.95M, Expands ADC Platform; Andelyn Biosciences to Manufacture AAV9-GM2 Gene…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-08-21-cdmo
published_at: 2026-08-21T00:00:03.562Z
last_updated: 2026-08-21T00:02:17.810Z
---

### Piramal Pharma Increases [Yapan Bio](/companies/yapan-bio) Stake to 74% for $7.95M, Expands ADC Platform
- Piramal Pharma acquired an additional 40.67% stake in Hyderabad-based CDMO [Yapan Bio](/companies/yapan-bio) for ₹76 crore ($7.95 million), raising total ownership to 74%.
- Integration strengthens Piramal's ADCelerate platform for antibody-drug conjugate development and expands large-molecule manufacturing capabilities within [Piramal Pharma Solutions](/companies/piramalpharmasolutions).

**Operational Impact**

[Piramal Pharma Solutions](/companies/piramalpharmasolutions) now controls [Yapan Bio](/companies/yapan-bio)'s Hyderabad biologics and vaccine manufacturing footprint as a subsidiary, directly expanding its integrated ADC development capacity from R&D through GMP in under 12 months.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-acquires-40-67-stake-in-yapan-bio-for-7-95m)*

---

### [Andelyn Biosciences](/companies/andelynbio) to Manufacture AAV9-GM2 Gene Therapy for Queen's University
- [Andelyn Biosciences](/companies/andelynbio) will develop and manufacture AAV9-GM2, a gene therapy for GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases), in partnership with Queen's University.
- Andelyn will deploy its AAV Curator Platform—a modular viral vector manufacturing process with proprietary cell line—to support yield and quality through clinical dosing.

**Operational Impact**

Andelyn's AAV Curator Platform deployment on the GM2 program demonstrates commercial-stage viral vector manufacturing capability and modular process scalability relevant to CDMO buyers evaluating gene-therapy manufacturing partners.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/andelyn-biosciences-partners-with-queens-university-on-aav9-gm2-gene-therapy)*

## References

1. [PharmaSource RSS — Piramal Pharma Increases Yapan Bio Stake to 74% for $7.95M, Expands ADC Platform](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-acquires-40-67-stake-in-yapan-bio-for-7-95m)
2. [PharmaSource RSS — Andelyn Biosciences to Manufacture AAV9-GM2 Gene Therapy for Queen's University](https://pharmasource.global/content/news/cdmo-news/andelyn-biosciences-partners-with-queens-university-on-aav9-gm2-gene-therapy)

Source: https://www.cdmo.directory/posts/daily-news-2026-08-21-cdmo